(News Bulletin 247) – Oddo BHF maintains its ‘outperformance’ opinion and its price target of 1050 Danish kroner on Novo Nordisk, after the announcement on Friday of clinical data ‘auspicious before the Oasis 1 trial in obese patients ( Rybelsus at a dose of 50mg)’.
The analyst recalls that the Danish laboratory had launched two parallel trials to evaluate Rybelsus (already approved at 14mg) at higher doses in patients with type 2 diabetes (PIONEER PLUS) and obese patients (Oasis) .
‘PIONEER PLUS is thus positive. The improvement is statistically significant at the two doses evaluated for a completely suitable safety profile,’ he specifies, considering that the offer of Novo in type 2 diabetes is thereby reinforced.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
